Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project

Background: Around 40% of ER+/HER2-breast carcinomas (BC) present mutations in the PIK3CA gene. Assessment of PIK3CA mutational status is required to identify patients eligible for treatment with PI3Kα inhibitors, with alpelisib currently the only approved tyrosine kinase inhibitor in this setting....

全面介紹

書目詳細資料

Principais autores:	Ana Peixoto, Luís Cirnes, Ana Luísa Carvalho, Maria João Andrade, Maria José Brito, Paula Borralho, Nuno Coimbra, Pedro M. Borralho, Ana Sofia Carneiro, Lisandra Castro, Lurdes Correia, Maria Rita Dionísio, Carlos Faria, Paulo Figueiredo, Ana Gomes, Joana Paixão, Manuela Pinheiro, Hugo Prazeres, Joana Ribeiro, Natália Salgueiro, Fernando C. Schmitt, Fátima Silva, Ana Rita Silvestre, Ana Carla Sousa, Joana Almeida-Tavares, Manuel R. Teixeira, Saudade André, José Carlos Machado
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2023-02-01
叢編:	Frontiers in Molecular Biosciences
主題:	advanced breast cancer ER+/HER2− PIK3CA mutations ring trial validation molecular pathology
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fmolb.2023.1082915/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!